LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE tablet, film coated

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
31-07-2023
제품 특성 요약 제품 특성 요약 (SPC)
31-07-2023

유효 성분:

LOSARTAN POTASSIUM (UNII: 3ST302B24A) (LOSARTAN - UNII:JMS50MPO89), HYDROCHLOROTHIAZIDE (UNII: 0J48LPH2TH) (HYDROCHLOROTHIAZIDE - UNII:0J48LPH2TH)

제공처:

Solco Healthcare US, LLC

INN (International Name):

LOSARTAN POTASSIUM

구성:

LOSARTAN POTASSIUM 50 mg

관리 경로:

ORAL

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, f

제품 요약:

Losartan potassium and hydrochlorothiazide tablets, USP are supplied as a film-coated tablet. Losartan/ Hydrochlorothiazide Color Shape Engraving NDC 43547-xxx-xx Bottle/ 30 Bottle/ 90 Bottle/ 1000 50/12.5 mg yellow capsule-shaped HH/211 423-03 423-09 423-11 100/12.5 mg white to off-white capsule-shaped HH/213 425-03 425-09 425-11 100/25 mg yellow capsule-shaped HH/212 424-03 424-09 424-11 Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from light.

승인 상태:

Abbreviated New Drug Application

환자 정보 전단

                                LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE- LOSARTAN POTASSIUM AND
HYDROCHLOROTHIAZIDE TABLET, FILM COATED
Solco Healthcare US, LLC
----------
FDA-APPROVED PATIENT LABELING
Dispense with Patient Information available at:
www.solcohealthcare.com/druglabeling/losartan-hctz-tablets.pdf
Patient Information
Losartan Potassium and Hydrochlorothiazide Tablets, USP
(loe-SAR-tanpoe-TAS-see-um and hye-droe-klor-oh-THYE-ah-zide)
50/12.5 mg, 100/12.5 mg, 100/25 mg
Rx only
Read the Patient Information that comes with losartan potassium and
hydrochlorothiazide tablets before you
start taking it and each time you get a refill. There may be new
information. This leaflet does not take the
place of talking with your doctor about your condition and treatment.
What is the most important information I should know about losartan
potassium and hydrochlorothiazide
tablets?
•
Losartan potassium and hydrochlorothiazide tablets can cause harm or
death to an unborn baby.
•
Talk to your doctor about other ways to lower your blood pressure if
you plan to become pregnant.
•
If you get pregnant while taking losartan potassium and
hydrochlorothiazide tablets tell your doctor
right away.
What are losartan potassium and hydrochlorothiazide tablets?
Losartan potassium and hydrochlorothiazide tablets contain 2
prescription medicines, an angiotensin receptor
blocker (ARB) and a diuretic (water pill). It is used to:
•
lower high blood pressure (hypertension). Losartan potassium and
hydrochlorothiazide tablets are not
usually the first medicine used to treat high blood pressure.
•
lower the chance of stroke in patients with high blood pressure and a
heart problem called left
ventricular hypertrophy (LVH). Losartan potassium and
hydrochlorothiazide tablets may not help
Black patients with this problem.
Losartan potassium and hydrochlorothiazide tablets have not been
studied in children less than 18 years old.
High Blood Pressure (hypertension). Blood pressure is the force in
your blood vessels when your heart beats
and when your heart rests. Y
                                
                                전체 문서 읽기
                                
                            

제품 특성 요약

                                LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE- LOSARTAN POTASSIUM
AND HYDROCHLOROTHIAZIDE TABLET, FILM COATED
SOLCO HEALTHCARE US, LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LOSARTAN POSTASSIUM
AND HYDROCHLOROTHIAZIDE​TABLETS SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING
INFORMATION FOR LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS.
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS, FOR ORAL USE.
INITIAL U.S. APPROVAL: 1995
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
WHEN PREGNANCY IS DETECTED, DISCONTINUE LOSARTAN POTASSIUM AND
HYDROCHLOROTHIAZIDE
TABLETS AS SOON AS POSSIBLE. DRUGS THAT ACT DIRECTLY ON THE
RENIN-ANGIOTENSIN SYSTEM
CAN CAUSE INJURY AND DEATH TO THE DEVELOPING FETUS. (5.1)
INDICATIONS AND USAGE
Losartan potassium and hydrochlorothiazide tablets are a combination
of losartan, an angiotensin II
receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated
for:
•
•
DOSAGE AND ADMINISTRATION
Hypertension
•
•
Hypertensive Patients with Left Ventricular Hypertrophy
•
DOSAGE FORMS AND STRENGTHS
Tablets (losartan potassium/hydrochlorothiazide content): 50/12.5 mg;
100/12.5 mg; and 100/25 mg. (3)
CONTRAINDICATIONS
•
•
•
WARNINGS AND PRECAUTIONS
•
•
•
•
•
ADVERSE REACTIONS
Most common adverse reactions (incidence ≥2% and greater than
placebo) are dizziness, upper
respiratory infection, cough, and back pain. (6.1)
Treatment of hypertension, to lower blood pressure. Lowering blood
pressure reduces the risk of fatal
and nonfatal cardiovascular events, primarily strokes and myocardial
infarctions. (1.1)
Reduction of the risk of stroke in patients with hypertension and left
ventricular hypertrophy. There is
evidence that this benefit does not apply to Black patients. (1.2)
Usual starting dose: 50/12.5 mg once daily. (2.1)
Titrate as needed to a maximum dose of 100/25 mg. (2.1)
Not controlled on monotherapy: Initiate with 50/12.5 mg. Titrate as
needed to a m
                                
                                전체 문서 읽기
                                
                            

이 제품과 관련된 검색 알림